GLUCOSENSOR Q APP END-USER LICENSE AGREEMENT (EULA) AND TERMS OF USE
GlucoSensor™ Q
Version: V010726
Effective date: 1 July 2026
Issued by: Maralvion sp. z o.o.
Applicable product: GlucoSensor Q Continuous Glucose Monitoring System, Model D1
Website: www.glucosensor.com
Contact: support@glucosensor.com
ARTICLE 1. DEFINITIONS
1.1 In this App EULA, the following terms have the meanings set out below.
1.2 “Account” means a user account created or used through the Website, webshop, App or related user account environment to access the App, activate or use App functionality, activate or manage a Sensor where applicable, manage support features or use related digital services in connection with GlucoSensor Q.
1.3 “App” means the GlucoSensor™ Q mobile application made available by or on behalf of Maralvion for use with the GlucoSensor™ Q System, including the user interface, Account environment, Sensor connection functionality, alerts, Reports, Share and Follow functionality, support functionality, updates and other digital features
1.4 “App EULA” means this App End User License Agreement for the GlucoSensor Q App.
1.5 “App Store” means Apple’s App Store, Google Play or any other authorised digital distribution platform through which the App is made available.
1.6 “Authorised Representative” means Firsteck Bio S.r.l., Via Salvatore Quasimodo 36/38, 40013 Castel Maggiore, Italy, acting as authorised representative of the Manufacturer within the European Union for GlucoSensor Q, where and to the extent indicated in the applicable regulatory documentation.
1.7 “Authorised Service Providers” means third party service providers engaged by Maralvion to support the operation of the App, customer support, hosting, analytics, marketing, technical support, compliance, administration or related services.
1.8 “Device” means the GlucoSensor™ Q System where that term is used in the context of CE marking, medical device law, the certificate, product labelling, the Instructions for Use (IFU), manufacturer approved regulatory documentation or mandatory product information.
1.9 “Digital Content Laws” means applicable EU and national consumer protection rules on contracts for the supply of digital content, digital services or goods with digital elements, including national laws implementing Directive (EU) 2019/770 and Directive (EU) 2019/771 where and to the extent applicable.
1.10 “Dreisam” or “Manufacturer” means Dreisam (Beijing) Medical Technology Co., Ltd., Liangshuihe 1st Street, Room 101, 1F, Building 9, Zone 1, Court 7, Beijing 100176, P.R.C., as legal manufacturer of the GlucoSensor™ Q System.
1.11 “GDPR” means Regulation (EU) 2016/679, the General Data Protection Regulation.
1.12 “GlucoSensor”, “GlucoSensor™ Q”, “we”, “us” or “our” means Maralvion, unless the context clearly refers to the GlucoSensor brand, the App, the Device, the Sensor, the GlucoSensor™ Q System or another GlucoSensor related service.
1.13 “GlucoSensor™ Q System” or “System” means the CE marked Class IIb GlucoSensor™ Q Continuous Glucose Monitoring system, Model D1, manufactured by Dreisam and made available by Maralvion under the GlucoSensor™ Q brand in selected European markets. The System consists of the Sensor and the App and is intended to be used in accordance with the Instructions for Use (IFU), product labelling and applicable product information.
1.14 “Health Data” means Personal Data relating to the physical or health status of a User, including glucose values, glucose trends, Time in Range, hypo and hyper events, alerts, reports, health related notes and other information that qualifies as data concerning health under the GDPR.
1.15 “Instructions for Use (IFU)” means the manufacturer’s instructions, warnings, contraindications, limitations, safety information and user guidance applicable to GlucoSensor Q.
1.16 “Manufacturer SDK” means the manufacturer supplied or manufacturer authorised software components, interfaces, libraries, communication protocols and related technical components used in connection with the App and the GlucoSensor™ Q System to support Sensor communication, glucose related functionality and related System operation, as supplied, authorised or specified by Dreisam.
1.17 “Maralvion” means Maralvion sp. z o.o., Pl. Władysława Andersa 3, 11th Floor, 61-894 Poznań, Poland, KRS: 0001235440.
1.18 “MDR” means Regulation (EU) 2017/745 on medical devices.
1.19 “Personal Data” has the meaning given to that term under the GDPR.
1.20 “Privacy Policy” means the GlucoSensor Q Privacy Policy published by Maralvion, as updated in accordance with its terms and applicable law.
1.21 “Reports” means summaries, charts, estimated statistics, glucose metrics, trend overviews, downloadable reports and other information generated by or through the App based on Sensor data and User input.
1.22 “Sensor” means the disposable GlucoSensor™ Q sensor assembly supplied in its applicator and intended to be applied, activated, worn, used, removed and replaced in accordance with the Instructions for Use (IFU). The applicator is supplied to place the Sensor and is not a separate reusable System component.
1.23 “Share and Follow” means any App feature that allows a User to share selected glucose data, alerts, trend information or related information with another person chosen by the User.
1.24 “Website” means the GlucoSensor website, webshop and related online account environment operated by or on behalf of Maralvion at www.glucosensor.com.
1.25 “User”, “you” or “your” means the individual who downloads, installs, accesses or uses the App.
ARTICLE 2. SCOPE, ACCEPTANCE AND LEGAL EFFECT
2.1 This App EULA governs your access to and use of the App. It applies to all Users who download, install, access or use the App, whether the App is obtained through an App Store or another authorised distribution channel.
2.2 By ticking an acceptance box in or for the App, logging into the App with an Account, activating App functionality, activating a Sensor through the App, using the App or continuing to use the App after being notified of updated terms, you agree to be bound by this App EULA, where such acceptance is legally valid.
2.3 If you do not agree to this App EULA, you must not use the App. If you have already installed the App and do not agree to this App EULA, you must stop using the App and remove it from your mobile device.
2.4 This App EULA applies together with the Privacy Policy, the Legal Disclaimer for the GlucoSensor Q App, the General Delivery Terms, the Returns and Refund Policy, the Sensor Replacement Policy, applicable product instructions, product labelling and mandatory safety information, where applicable. Where your use also involves the Website, the Website EULA and Terms of Use and the Website Legal Disclaimer may also apply.
2.5 In the event of a conflict concerning the official intended purpose, target population, indications, contraindications, warnings, limitations, CE marking, product identification, product performance specifications or mandatory information required for the safe and correct use of GlucoSensor Q, the applicable product labelling, mandatory regulatory information, safety notices and Instructions for Use (IFU), where applicable to that specific matter, prevail for that matter only. This does not make the IFU the controlling document for privacy, App licensing, commercial terms, data protection, support procedures, dispute handling or other legal matters governed by this App EULA or the applicable legal document.
2.6 In the event of a conflict between this App EULA and the Privacy Policy concerning the processing of Personal Data or Health Data, the Privacy Policy prevails for privacy and data protection matters.
2.7 This App EULA does not limit any mandatory rights that you may have under applicable consumer protection law, Digital Content Laws, medical device law, product liability law or data protection law.
2.8 The App is made available for use in selected countries where Maralvion makes GlucoSensor Q available. Certain features, languages, services, integrations or support options may not be available in every country.
2.9 A paper copy of the IFU is included in each Sensor package. Maralvion may also make the current IFU available through the Website, the user account environment or customer support channels. If you cannot access the IFU, do not understand the IFU or need an additional copy, you should contact Maralvion at support@glucosensor.com before using or continuing to use GlucoSensor Q.
ARTICLE 3. APP OPERATOR, MANUFACTURER AND REGULATORY ROLES
3.1 The App is operated by Maralvion. Maralvion makes GlucoSensor™ Q available to Users in selected European markets and acts within its own role as App operator, seller and EU importer where applicable.
3.2 Dreisam is the legal Manufacturer of the GlucoSensor™ Q System. Dreisam remains responsible within its manufacturer role for System design, manufacture, conformity assessment, CE marking, technical documentation, clinical performance, Sensor technology, the Manufacturer SDK, manufacturer supplied or manufacturer authorised software components and other manufacturer obligations under the MDR.
3.3 Firsteck Bio S.r.l. acts as Authorised Representative of the Manufacturer within the European Union where and to the extent indicated in the applicable regulatory documentation.
3.4 Maralvion operates the App and uses the GlucoSensor brand, related content, platform elements, domain names, trademarks and intellectual property rights either as owner or under licence from the relevant rights holder.
3.5 Maralvion may use Authorised Service Providers for customer support, marketing, content, operational, technical, administrative, hosting, analytics, compliance and related support services. Where such service providers process Personal Data on behalf of Maralvion, they do so in accordance with the Privacy Policy and applicable data processing arrangements.
3.6 Maralvion is not the Manufacturer of the GlucoSensor™ Q System and does not independently design, manufacture, validate, alter or replace the Sensor, the Manufacturer SDK or the manufacturer supplied or manufacturer authorised functionality used to generate glucose related information.
3.7 Within its own role, Maralvion may operate, configure, localise and maintain App elements relating to the Account environment, user interface, language versions, support flows, content, notifications, display of Reports, customer communications and related user experience elements. Maralvion must not be understood as providing an independent glucose measurement algorithm, independent glucose calculation engine, independent clinical decision system or independent medical interpretation layer through the App.
3.8 Maralvion remains responsible only for legal obligations that apply to Maralvion within its own role as described in this App EULA, the Privacy Policy and applicable law.
3.9 Maralvion may handle product related information and cooperate with Dreisam, the Authorised Representative, service providers or other relevant parties where this is required or appropriate under applicable law.
ARTICLE 4. MEDICAL DEVICE NOTICE AND INTENDED USE
4.1 GlucoSensor™ Q is a CE marked Class IIb Continuous Glucose Monitoring System, Model D1, manufactured by Dreisam and made available by Maralvion under the GlucoSensor™ Q brand in selected European markets. The System consists of the Sensor and the App. The certified intended purpose is to provide real time, continuous glucose monitoring for adults aged 18 years and older to manage diabetes. Within its certified intended purpose, the System is intended to support glucose monitoring and diabetes management by providing glucose information that may be used in accordance with the Instructions for Use (IFU), product labelling, safety information and appropriate professional medical guidance. The App does not itself provide medical advice, diagnosis, treatment, emergency care or professional healthcare services.
4.2 The App is intended to support the use of the GlucoSensor™ Q System by displaying glucose information and related App functionality in accordance with the IFU, product labelling, safety information and this App EULA.
4.3 The App, the Sensor, glucose values, alerts, Reports, trend information and other App outputs must be used only in accordance with the IFU, this App EULA, the Legal Disclaimer for the GlucoSensor Q App and the safety information provided with or through GlucoSensor Q.
Unless expressly stated otherwise in the applicable Instructions for Use (IFU), product labelling or manufacturer approved regulatory documentation, GlucoSensor Q has not been specifically tested, clinically validated or approved for use during pregnancy or for gestational diabetes. If you are pregnant, have gestational diabetes, suspect that you may have gestational diabetes or are being monitored for pregnancy related glucose concerns, you should use GlucoSensor Q only with appropriate medical guidance and must not rely on the App, the Sensor, glucose values, alerts, Reports, trend information or other App outputs as a substitute for pregnancy related diabetes care, clinically recommended glucose monitoring, laboratory testing or instructions from a qualified healthcare professional.
ARTICLE 5. ELIGIBILITY, ACCOUNT AND USER INFORMATION
5.1 The App is intended only for Users aged 18 years and older.
5.2 You may use the App only if you are legally capable of entering into a binding agreement and your use of GlucoSensor Q is consistent with the Instructions for Use (IFU).
5.3 You need an Account to log into the App, activate the App, activate or manage a Sensor where applicable and use certain App features. The Account may be created through the Website, webshop, user account environment, App or another authorised registration flow made available by Maralvion. Where Maralvion enables a shared Account environment, the same Account credentials created through the Website or webshop may be used to log into the App, subject to App activation, verification, technical availability and applicable security requirements. The Account may be linked to your purchase, order, email address, Sensor information, System information, Sensor activation, customer support history and other information necessary to operate the App and support GlucoSensor Q.
5.4 You must provide accurate, current and complete Account information, whether provided through the Website, webshop, App, user account environment or support channels. You must promptly update your information if it changes.
5.5 You are responsible for keeping your login details confidential and for activities carried out through your Account in connection with the App, unless those activities result from a security failure for which Maralvion is legally responsible..
5.6 You must not share your login credentials with another person. Share and Follow functionality must be used only through the authorised sharing functionality provided in the App.
5.7 Maralvion may refuse, suspend or restrict access to the App where this is necessary to protect App security, prevent misuse, comply with legal obligations, protect other Users, investigate suspected fraud or address serious technical or safety concerns.
5.8 If you believe that your Account has been accessed without authorisation, you must contact support@glucosensor.com without undue delay.
ARTICLE 6. LICENSE TO USE THE APP
6.1 Subject to your compliance with this App EULA, Maralvion grants you a limited, personal, non exclusive, non transferable licence to download, install and use the App for your own lawful personal use in connection with the GlucoSensor Q System, for as long as the App is made available to you and your access has not been suspended or terminated in accordance with this App EULA and mandatory applicable law.
6.2 This licence does not transfer ownership of the App, the GlucoSensor brand, the software, the user interface, the underlying technology, the content, the database structure, report formats, report templates, documentation or any intellectual property rights to you. This does not affect your rights in your own Personal Data or Health Data as described in the Privacy Policy.
6.3 You may use the App only on a compatible mobile device that you own or lawfully control and only in accordance with this App EULA, the App Store rules, the Instructions for Use (IFU) and applicable law.
6.4 You must not copy, modify, adapt, translate, reverse engineer, decompile, disassemble, attempt to derive source code from, circumvent security features of, interfere with or create derivative works based on the App, except to the extent that such restriction is prohibited by mandatory applicable law.
6.5 This licence also applies to App updates, corrections, security patches, compatibility updates and modified functionality made available by or on behalf of Maralvion, unless separate terms are provided.
6.6 Some App features may not be available in all countries, languages, operating systems, mobile devices or App versions.
ARTICLE 7. GLUCOSENSOR Q APP FUNCTIONALITY
7.1 The App is designed for use with the GlucoSensor Q System. It is not intended for use with unsupported sensors, unrelated CGM systems or unauthorised third party devices.
7.2 GlucoSensor Q uses an integrated sensor design and does not require or use a separate reusable transmitter.
7.3 The App and the GlucoSensor Q System may require activation, Bluetooth connectivity, compatible hardware, compatible operating system versions, internet access, Account access and correct Sensor application in accordance with the Instructions for Use (IFU).
7.4 Depending on the applicable App version, configuration, country availability and technical setup, the App may display real time glucose information, historical glucose data, trend information, alerts, Reports, user notes, Account information, support features and other functionality made available in or through the App.
ARTICLE 8. MANUFACTURER SDK AND MEASUREMENT FUNCTIONALITY
8.1 The App may include, access or interact with the Manufacturer SDK, manufacturer supplied or manufacturer authorised software components, firmware interfaces, libraries, communication protocols and related technical components used in connection with the GlucoSensor™ Q System.
8.2 Glucose related information displayed or made available through the App may depend on the Sensor, the Manufacturer SDK, manufacturer supplied or manufacturer authorised software components, correct use by the User, mobile device functionality, software configuration, connectivity and other technical or practical factors.
8.3 The Manufacturer SDK and manufacturer supplied or manufacturer authorised software components are used by Maralvion as supplied, authorised or specified by the Manufacturer. Maralvion does not modify the Manufacturer SDK, the Manufacturer’s underlying glucose measurement algorithm, sensor calculation logic, calibration logic, measurement logic or manufacturer controlled medical measurement functionality.
8.4 Maralvion may operate, configure, localise and maintain App elements relating to the user interface, user experience, Account environment, local market configuration, content, support flows, notifications, language versions, visual presentation, customer communications and other non measurement related App components within Maralvion’s own role.
8.5 Maralvion must not alter, override, replace or independently validate the Manufacturer SDK, underlying glucose measurement algorithm, sensor calculation logic, calibration logic, measurement logic, manufacturer controlled medical measurement functionality, intended purpose, risk classification or safety characteristics of the GlucoSensor™ Q System, except where such action is expressly authorised by the Manufacturer and handled within the applicable regulatory framework before implementation.
8.6 Where the Manufacturer SDK, manufacturer supplied or manufacturer authorised software components or related technical components are used in connection with the App and the GlucoSensor™ Q System, Maralvion relies on those components as supplied, authorised or specified by the Manufacturer.
8.7 Nothing in this App EULA transfers manufacturer responsibility for System design, Sensor technology, the Manufacturer SDK, manufacturer supplied or manufacturer authorised software components, glucose related functionality or manufacturer controlled medical measurement output from the Manufacturer to Maralvion, except to the extent mandatory applicable law imposes obligations on Maralvion within its own role.
8.8 The App must not be understood as providing an independent medical algorithm, independent glucose calculation engine, independent clinical decision system, independent diagnostic service or independent medical interpretation layer by Maralvion. The App displays or presents information generated by or in connection with the GlucoSensor™ Q System, subject to the limitations set out in this App EULA, the Legal Disclaimer for the GlucoSensor™ Q App, App warnings, product labelling and applicable product information.
ARTICLE 9. USER RESPONSIBILITIES
9.1 You must use the App and GlucoSensor Q only in accordance with this App EULA, the Instructions for Use (IFU), the safety information provided with or through GlucoSensor Q, applicable law and any instructions provided by your qualified healthcare professional.
9.2 You are responsible for correctly applying, activating, using, monitoring, removing and replacing the Sensor in accordance with the Instructions for Use (IFU).
9.3 You must not use the Sensor, the App or the GlucoSensor Q System if the product packaging is damaged, the Sensor appears defective, the Sensor has expired, the App displays a safety warning that prevents use, the Instructions for Use (IFU) indicate that use is not permitted, or the conditions for safe use are not met.
9.4 You must check that the App is operating correctly before relying on glucose information, alerts, Reports or Share and Follow functionality. This includes checking Bluetooth settings, notification settings, sound settings, mobile device battery status, internet connectivity, App permissions and any warnings shown in the App.
9.5 You must keep your mobile device sufficiently charged, secure, updated and available during use of the App.
9.6 You must not disable, override, bypass or interfere with App permissions, safety warnings, Sensor communication, alert settings, software safeguards, Account security features or other functionality required for safe and proper use.
9.7 You are responsible for the accuracy of information that you enter into the App, including notes, symptoms, meals, medication, activity, lifestyle information and other user entered information.
ARTICLE 10. WARNINGS, ALERTS AND MEDICAL DECISION MAKING
10.1 The App may provide glucose values, alerts, notifications, trend information, Reports and other outputs intended to support glucose awareness and diabetes management in accordance with the certified intended purpose of GlucoSensor Q.
10.2 Alerts and notifications may depend on Sensor function, App settings, Bluetooth connectivity, internet connectivity, mobile device settings, operating system permissions, sound settings, focus mode, battery status, server availability and other factors outside Maralvion’s direct control. Maralvion does not guarantee that alerts or notifications will always be generated, transmitted, received, heard, noticed or acted upon in time.
10.3 You must not rely on the App as your only method for detecting or responding to hypoglycaemia, hyperglycaemia, rapidly changing glucose levels, illness, symptoms or other medical concerns.
10.4 If glucose information shown in the App does not match your symptoms, expectations, physical condition, pregnancy related medical situation or other relevant medical circumstances, you must follow the Instructions for Use (IFU), use an alternative method to confirm your glucose level where appropriate and seek medical advice where necessary.
10.5 The App does not provide emergency medical monitoring, emergency response services, professional medical supervision, remote patient monitoring by Maralvion or guaranteed intervention by any third party.
10.6 You remain responsible for medical decisions, treatment decisions, insulin dosing, medication changes, dietary actions, exercise decisions and responses to alerts, unless such responsibility legally rests with a qualified healthcare professional involved in your care. Maralvion does not provide medical advice and does not instruct you to start, stop or change any medication, insulin dose, therapy, treatment plan or medical intervention.
ARTICLE 11. SHARE AND FOLLOW FEATURES
11.1 The App may include Share and Follow functionality that allows you to share selected glucose information, alerts, trend information or related information with one or more persons chosen by you.
11.2 You decide whether to use Share and Follow functionality, which person you invite, which information you share and when you stop sharing, subject to the technical options available in the App.
11.3 You must share Health Data only with persons you trust and only after considering the privacy, safety and personal consequences of sharing such information.
11.4 You are responsible for ensuring that the contact details of each invited Share and Follow recipient are accurate and that the intended recipient is the person who receives the invitation or access.
11.5 You may withdraw or change Share and Follow access through the App where this functionality is available. Withdrawal may not affect information that was already received, stored, copied, disclosed or otherwise used by the recipient before access was withdrawn.
11.6 A Share and Follow recipient is responsible for their own use, storage, disclosure and protection of information received through Share and Follow functionality.
11.7 Maralvion is not responsible for any further disclosure, misuse, copying, forwarding, storage, interpretation or use of shared information by a Share and Follow recipient, except where Maralvion is legally responsible under mandatory applicable law.
11.8 Share and Follow functionality is not an emergency service, professional monitoring service, caregiver service or guaranteed response system.
11.9 Maralvion may suspend, restrict or modify Share and Follow functionality where necessary for security, safety, technical, legal, regulatory or operational reasons.
ARTICLE 12. REPORTS, TRENDS, ANALYTICS AND AUTOMATED INSIGHTS
12.1 The App may generate Reports, charts, summaries, glucose statistics, trend analyses, Time in Range information, pattern detection, estimated metrics or other automated insights based on sensor data, user entered information and predefined software logic.
12.2 Reports, trends, statistics and automated insights are intended to support glucose awareness, glucose trend review, diabetes management and informed discussions with a qualified healthcare professional where appropriate, within the certified intended purpose of GlucoSensor Q. They do not replace professional medical judgment, medical advice, diagnosis, treatment instructions, insulin dosing instructions or emergency care.
12.3 Reports, trends, statistics and automated insights may be incomplete, delayed, estimated, affected by missing data or influenced by Sensor performance, user behaviour, connectivity, mobile device settings, App configuration, input accuracy and other technical or practical factors.
12.4 Where Reports, trends, statistics or insights are based on glucose measurement outputs, Article 8 applies.
12.5 The App does not make solely automated decisions that produce legal effects concerning you or similarly significantly affect you.
12.6 You must not use Reports, trend analyses, estimated statistics or automated insights as the sole basis for treatment decisions, insulin dosing, medication adjustments or urgent medical action.
ARTICLE 13. SOFTWARE UPDATES, MAINTENANCE AND AVAILABILITY
13.1 Maralvion may provide and, where required by applicable law, will provide App updates, security patches, maintenance releases, compatibility updates, language updates, interface changes, bug fixes, support improvements, regulatory updates or other modifications where necessary or appropriate for security, compatibility, performance, regulatory compliance, user support, App Store compliance, continued operation with GlucoSensor Q or conformity under applicable Digital Content Laws.
13.2 Updates may be required to maintain or restore the security, compatibility, performance, regulatory compliance, data protection, user support, App Store compliance, continued operation or legal conformity of the App.
13.3 You must install App updates within a reasonable time after they become available, especially where an update is necessary for security, safety, compatibility, regulatory compliance, conformity under applicable Digital Content Laws or correct App operation.
13.4 If you do not install required updates within a reasonable time after being informed of their availability and consequences, certain App features may stop working, become inaccurate, become unavailable or no longer be supported, except where mandatory applicable law provides otherwise.
13.5 Updates may include manufacturer supplied or manufacturer authorised components, compatibility components or technical interfaces required for use with GlucoSensor™ Q. Maralvion may implement such updates within its own role, provided that this does not alter, override or replace the Manufacturer’s underlying glucose measurement logic, sensor calculation logic or manufacturer controlled medical measurement functionality unless expressly authorised by the Manufacturer and handled within the applicable regulatory framework.
13.6 Maralvion may temporarily suspend, restrict or interrupt access to the App where necessary for maintenance, security, technical updates, emergency repairs, legal compliance, App Store requirements, regulatory obligations or protection of Users.
13.7 Maralvion will make reasonable efforts to maintain App availability, but does not guarantee uninterrupted, error free or continuous availability of the App, servers, connectivity, notifications, Reports or Share and Follow functionality.
13.8 Maralvion may discontinue or replace outdated App versions where this is necessary for security, compatibility, regulatory, operational or legal reasons.
13.9 Nothing in this Article 13 limits Maralvion’s obligation to provide updates, security updates or corrective updates where and for as long as such updates are required under mandatory applicable law.
ARTICLE 14. CONNECTIVITY, COMPATIBILITY AND THIRD PARTY DEVICES
14.1 Use of the App may require a compatible mobile device, compatible operating system, Bluetooth, internet access, sufficient storage capacity, notification permissions, location or nearby device permissions where required by the operating system and other technical requirements.
14.2 Maralvion may publish compatibility information for supported mobile devices, operating systems, App versions, languages and countries. Compatibility may change as mobile device manufacturers, operating system providers or App Stores update their systems.
14.3 Maralvion does not guarantee compatibility with every mobile device, operating system version, wearable device, accessory, browser, network, mobile provider, third party app or third party service.
14.4 You are responsible for ensuring that your mobile device and settings meet the technical requirements for use of the App.
14.5 Operating system updates, mobile device updates, App Store policies, Bluetooth changes, permission changes, battery saving settings, focus settings, security software or third party services may affect App functionality, data transmission, notifications, alerts or Share and Follow functionality.
ARTICLE 15. DATA PROTECTION AND HEALTH DATA
15.1 Use of the App involves the processing of Personal Data and Health Data, including glucose related information. Such processing is described in the Privacy Policy.
15.2 Maralvion processes Personal Data and Health Data in accordance with the GDPR, applicable data protection law and the Privacy Policy.
15.3 Health Data is sensitive information. You must carefully consider what information you enter into the App and with whom you share information through Share and Follow functionality or by exporting, downloading, forwarding or showing Reports.
15.4 Maralvion does not sell your Health Data.
15.5 You must not enter Personal Data or Health Data of another person into your App Account unless you have a lawful basis and the legal right to do so.
15.6 Privacy related requests must be submitted in accordance with the Privacy Policy or by contacting support@glucosensor.com.
ARTICLE 16. SECURITY, ACCOUNT PROTECTION AND UNAUTHORISED USE
16.1 Maralvion applies technical and organisational measures intended to protect the App, Accounts, Personal Data, Health Data, systems and related services against unauthorised access, accidental loss, misuse, alteration, disclosure and other security risks.
16.2 You are responsible for protecting your mobile device, App access, login credentials, email account, operating system, screen lock, password, biometric access and other security settings.
16.3 You must use a secure password and must not share your login credentials with another person.
16.4 You must promptly notify Maralvion at support@glucosensor.com if you suspect unauthorised access, Account misuse, data loss, security vulnerability, compromised login credentials or another security incident related to the App.
16.5 No digital system can be guaranteed to be completely secure. Maralvion does not guarantee absolute security, but will act in accordance with applicable legal obligations where a security incident affects Personal Data, Health Data, App security or medical device related safety.
ARTICLE 17. CUSTOMER SUPPORT, COMPLAINTS AND SAFETY RELATED REPORTING
17.1 Maralvion may provide customer support for the App, GlucoSensor Q, Account access, orders, technical questions, product use questions, complaints and other support matters through the official GlucoSensor support channels.
17.2 Support requests must be submitted through the support channels made available through the Website, the App or by contacting support@glucosensor.com.
17.3 When contacting support, you must provide accurate and complete information reasonably necessary to assess your request, including relevant App information, Sensor information, order information, screenshots, error messages, Sensor batch information, Sensor activation information, usage details and a description of the issue where applicable.
17.4 Maralvion may request additional information where reasonably necessary to assess technical issues, product complaints, suspected defects, safety concerns, warranty questions, replacement requests, cybersecurity concerns, data protection questions or medical device related reports.
17.5 You must not submit false, misleading, incomplete or manipulated information in connection with a support request, complaint, replacement request, refund request, warranty request, safety related report or regulatory enquiry.
17.6 If you experience a product issue that may affect safe use, including repeated device malfunction, unexpected Sensor behaviour, incorrect or inconsistent glucose readings, skin reaction, alert failure, data loss or a cybersecurity concern, you should contact Maralvion through the official GlucoSensor support channels so that the matter can be assessed and handled where required.
17.7 Maralvion may assess, document, investigate, escalate or forward product related information where necessary for customer support, product safety, quality management, regulatory compliance or cooperation with Dreisam, the Authorised Representative or other relevant parties.
17.8 Maralvion may refuse or limit support where a request concerns unauthorised use, unsupported devices, modified software, unofficial apps, unsupported sensors, altered operating systems, misuse, abuse, fraudulent requests or use outside the Instructions for Use (IFU).
17.9 Customer support provided by Maralvion does not constitute medical advice, diagnosis, treatment, professional clinical monitoring or emergency assistance.
ARTICLE 18. MEDICAL DEVICE SAFETY AND REGULATORY COOPERATION
18.1 GlucoSensor Q is subject to medical device requirements, including requirements relating to product safety monitoring, complaint handling and regulatory cooperation.
18.2 Where necessary, Maralvion may collect, assess, document, retain and forward relevant product related information to Dreisam, the Authorised Representative, service providers, competent authorities or other relevant parties for product safety, quality management, technical investigation, corrective action, regulatory compliance or legal obligations.
18.3 Maralvion may contact you regarding a reported issue, product safety matter, technical issue, replacement procedure, App update or other matter relevant to the safe and compliant use of GlucoSensor Q.
18.4 Maralvion may suspend, modify, restrict or discontinue certain App features where necessary to address product safety, cybersecurity, quality, regulatory, legal or technical concerns.
18.5 Nothing in this Article limits mandatory rights, mandatory reporting obligations or regulatory powers under applicable medical device law.
ARTICLE 19. INTELLECTUAL PROPERTY RIGHTS
19.1 The App, GlucoSensor brand, trademarks, trade names, logos, domain names, user interface, design elements, text, images, content, documentation, report formats, report templates, database structures, software, configuration, translations and related materials are protected by intellectual property rights, contractual rights and other legal protections.
19.2 The GlucoSensor brand, domain names, platform elements, content, trademarks and related intellectual property rights are owned by Maralvion and/or licensed to Maralvion by the relevant rights holder.
19.3 Dreisam and/or its licensors retain all rights in the GlucoSensor™ Q System, Sensor technology, applicator technology, Manufacturer SDK, manufacturer supplied or manufacturer authorised software components, firmware interfaces, technical documentation, measurement logic, glucose related functionality and other manufacturer controlled technology.
19.4 Maralvion and/or its licensors retain all rights in the GlucoSensor brand, App environment, Account environment, user interface, local market configuration, support flows, language versions, content, visual presentation, non measurement related App components and related services, except where such rights belong to Dreisam, App Stores, service providers or other relevant third parties.
19.5 You receive only the limited licence expressly granted under this App EULA. No other rights are granted to you by implication, exhaustion, estoppel or otherwise.
19.6 You must not remove, obscure, alter or misuse any copyright notice, trademark notice, medical device notice, ownership notice, safety notice, legal notice or other proprietary marking shown in or with the App.
19.7 You must not use the GlucoSensor name, GlucoSensor Q name, logos, trademarks, trade dress, product images, App screenshots, report formats, content or related materials for commercial purposes without prior written consent from Maralvion or the relevant rights holder.
19.8 You must not commercially exploit the App, App content, report formats, report templates, data structures, software, SDK components, user interface or related materials except as expressly permitted by this App EULA or mandatory applicable law.
ARTICLE 20. PROHIBITED USE
20.1 You must use the App only for lawful personal use in connection with the GlucoSensor Q System and in accordance with this App EULA, the Instructions for Use (IFU) and applicable law.
20.2 You must not use the App for unlawful, fraudulent, harmful, abusive, misleading, unsafe, unauthorised, commercial, competitive, regulatory non compliant or medical device non compliant purposes.
20.3 You must not use the App to provide medical services, remote patient monitoring services, clinical services, commercial analytics services, research services, professional monitoring services, emergency response services or third party data services without Maralvion’s prior written consent and without complying with all applicable legal and regulatory requirements.
20.4 You must not use the App to monitor another person without that person’s knowledge, consent and legal authorisation.
20.5 You must not upload, enter, transmit or share unlawful, false, misleading, defamatory, abusive, discriminatory, harmful, obscene, fraudulent, infringing, privacy violating or malicious content through the App.
20.6 You must not interfere with, overload, disrupt, damage, circumvent security features of, scan, scrape, extract data from or attempt to gain unauthorised access to the App, the GlucoSensor Q System, Maralvion systems, Dreisam systems, service provider systems, Accounts, servers, APIs, SDK components or technical interfaces.
20.7 You must not use the App with unauthorised sensors, unofficial software, modified App versions, unsupported devices, emulators, automated tools, rooted devices, jailbroken devices or altered operating systems where this may affect safety, performance, cybersecurity, data integrity or regulatory compliance.
20.8 You must not use the App to develop, train, test, validate, benchmark, reverse engineer or improve competing products, services, algorithms, datasets, software, glucose monitoring systems, medical device systems or analytics tools.
20.9 You must not misrepresent your identity, create Accounts using false information, impersonate another person, submit fraudulent support requests or interfere with the lawful use of the App by other Users.
20.10 Maralvion may suspend, restrict or terminate access to the App where it reasonably believes that the App is being used in breach of this Article 20 or where such action is necessary for safety, security, legal, regulatory or operational reasons.
ARTICLE 21. THIRD PARTY SERVICES AND APP STORES
21.1 The App may depend on or interact with third party services, including App Stores, operating systems, mobile devices, Bluetooth functionality, cloud hosting providers, analytics tools, customer support tools, payment providers, email providers, notification services and other service providers.
21.2 Third party services may be subject to separate terms, privacy notices, technical requirements, availability limitations and policies issued by the relevant third party.
21.3 Maralvion is not responsible for third party services, third party terms, third party privacy practices, third party availability, App Store decisions, operating system changes, device manufacturer changes, network failures, mobile provider failures or other third party acts or omissions, except where Maralvion is legally responsible under mandatory applicable law.
21.4 App Stores may impose rules regarding downloads, updates, payments, subscriptions, refunds, device compatibility, content, availability, account access and termination. Those rules apply in addition to this App EULA where relevant.
21.5 Where a third party service is required for App functionality, suspension, restriction, change or discontinuation of that third party service may affect the App, alerts, Reports, Share and Follow functionality, Account access, support features or other App features.
21.6 Maralvion may replace, add, remove or modify third party service providers where reasonably necessary for security, functionality, compliance, operational continuity, commercial reasons or improvement of the App, subject to the Privacy Policy and applicable law.
ARTICLE 22. APPLE SPECIFIC TERMS
22.1 This Article 22 applies where the App is downloaded from or used through Apple’s App Store.
22.2 This App EULA is concluded between you and Maralvion only, and not with Apple. As between you, Maralvion and Apple, Maralvion is responsible for the App and its content, subject to this App EULA and applicable law.
22.3 The licence granted to you for the App is limited to a non transferable licence to use the App on any Apple branded product that you own or control and as permitted by Apple’s applicable App Store rules. The App may also be accessed and used by other accounts associated with you through Apple’s family sharing or volume purchasing features where permitted by Apple.
22.4 Apple has no obligation to provide maintenance or support services for the App. Maralvion is responsible for App support as set out in this App EULA.
22.5 If the App fails to conform to any applicable warranty, you may notify Apple where permitted by Apple’s App Store rules. To the maximum extent permitted by applicable law, Apple will have no other warranty obligation with respect to the App.
22.6 Maralvion, and not Apple, is responsible for addressing claims by you or any third party relating to the App or your possession or use of the App, including product liability claims, claims that the App fails to conform to applicable legal or regulatory requirements and claims arising under consumer protection, privacy or similar legislation, subject to this App EULA and applicable law.
22.7 If a third party claims that the App or your possession and use of the App infringes that third party’s intellectual property rights, Maralvion, and not Apple, is responsible for the investigation, defence, settlement and discharge of such intellectual property infringement claim, subject to this App EULA and applicable law.
22.8 You represent and warrant that you are not located in a country that is subject to a United States Government embargo or that has been designated by the United States Government as a terrorist supporting country, and that you are not listed on any United States Government list of prohibited or restricted parties.
22.9 You must comply with applicable third party terms of agreement when using the App.
22.10 Apple and Apple’s subsidiaries are third party beneficiaries of this App EULA. Upon your acceptance of this App EULA, Apple has the right to enforce this App EULA against you as a third party beneficiary.
ARTICLE 23. GOOGLE PLAY SPECIFIC TERMS
23.1 This Article 23 applies where the App is downloaded from or used through Google Play.
23.2 This App EULA is concluded between you and Maralvion only, and not with Google. Maralvion is responsible for the App and its content, subject to this App EULA and applicable law.
23.3 Your use of the App through Google Play may also be subject to Google Play terms, policies, technical requirements, account rules, payment rules and refund rules.
23.4 Google has no obligation to provide maintenance or support services for the App. Maralvion is responsible for App support as set out in this App EULA.
23.5 Google is not responsible for addressing claims by you or any third party relating to the App or your possession or use of the App, except to the extent Google is legally responsible under mandatory applicable law.
23.6 Where Google Play rules conflict with this App EULA, the Google Play rules may apply to App Store distribution, download, payment, refund, device compatibility or account related matters to the extent required by Google Play or mandatory applicable law.
ARTICLE 24. STATUTORY DIGITAL CONTENT RIGHTS, WARRANTIES AND CONFORMITY
24.1 The App is provided with reasonable care and skill and is intended to support use of GlucoSensor Q in accordance with the Instructions for Use (IFU), this App EULA and applicable law.
24.2 If you are a consumer, mandatory Digital Content Laws apply to the App where and to the extent the App qualifies as digital content or a digital service supplied in connection with GlucoSensor Q, including where the App is supplied as part of, or is necessary for, a consumer purchase of GlucoSensor Q.
24.3 Where required by applicable Digital Content Laws, Maralvion will provide updates, including security updates, corrective updates and compatibility updates, that are necessary to keep the App in conformity for the period required by mandatory applicable law and for as long as the App is supplied in connection with supported use of GlucoSensor Q.
24.4 If the App does not conform to mandatory legal requirements that apply to it, you may have statutory remedies under applicable Digital Content Laws or other consumer protection laws. Depending on the circumstances and applicable law, such remedies may include having the App brought into conformity, receiving a proportionate price reduction, terminating the relevant contract or exercising other mandatory remedies available by law.
24.5 Statutory remedies may be limited or unavailable where the lack of conformity is caused by circumstances for which Maralvion is not legally responsible, including use outside applicable product instructions, product labelling, safety information or the Instructions for Use (IFU), failure to install required updates after being clearly informed of the availability of the update and the consequences of not installing it, use with unsupported devices, unauthorised modifications, misuse, third party failures outside Maralvion’s responsibility or incompatible technical environments, except where mandatory applicable law provides otherwise.
24.6 Nothing in this App EULA limits or excludes mandatory statutory rights that you may have under applicable consumer protection law, Digital Content Laws, medical device law, product liability law, data protection law or other mandatory applicable law.
24.7 Maralvion does not warrant that the App will be uninterrupted, error free, continuously available, compatible with every mobile device or operating system, immune from all security risks or free from all defects.
24.8 Maralvion does not warrant that alerts, notifications, Reports, Share and Follow functionality, data transmission, cloud synchronisation or third party integrations will always be available, accurate, complete, timely, received, heard, noticed or acted upon.
24.9 Maralvion does not provide any warranty that the App will meet your individual medical expectations, treatment goals, lifestyle goals, clinical outcomes, reimbursement expectations, insurance requirements or personal preferences.
24.10 Any commercial warranty, replacement right, refund right or return right relating to the Sensor or GlucoSensor Q System is governed by the applicable General Delivery Terms, Returns and Refund Policy, Sensor Replacement Policy and mandatory applicable law.
ARTICLE 25. LIMITATION OF LIABILITY
25.1 Nothing in this App EULA excludes or limits liability, rights or remedies to the extent that such exclusion or limitation is not permitted under mandatory applicable law.
25.2 The limitations and exclusions in this Article 25 apply only to the extent permitted by mandatory applicable law and shall be interpreted so as not to limit any liability, rights or remedies that cannot lawfully be limited or excluded.
25.3 Maralvion remains responsible only for obligations and liabilities that mandatory applicable law imposes on Maralvion within its own role and only to that extent. Nothing in this Article extends Maralvion’s role beyond the roles expressly described in this App EULA.
25.4 Subject to Articles 25.1 to 25.3, Maralvion is not liable for damage to the extent caused by use of the App or GlucoSensor Q contrary to this App EULA, the Instructions for Use (IFU), safety information, App warnings, applicable law or instructions from a qualified healthcare professional.
25.5 Subject to Articles 25.1 to 25.3, Maralvion is not liable for damage to the extent caused by incorrect Sensor application, incorrect Sensor use, delayed Sensor replacement, ignored warnings, ignored symptoms, inaccurate user entered information, disabled notifications, disabled permissions, low battery, unavailable mobile device, incompatible mobile device, altered operating system, unsupported device, unauthorised accessories, unofficial apps, misuse or failure to follow the Instructions for Use (IFU).
25.6 Subject to Articles 25.1 to 25.3, Maralvion is not liable for damage to the extent caused by failures of third party devices, operating systems, App Stores, mobile networks, internet providers, Bluetooth functionality, cloud providers, wearable devices, notification systems, email providers, customer support tools, payment providers or other third party services outside Maralvion’s reasonable control.
25.7 Subject to Articles 25.1 to 25.3, Maralvion is not liable for missed, delayed, incomplete, inaccurate, unheard, unnoticed or unacted upon alerts, notifications, Reports, Share and Follow messages or data transmissions to the extent the failure results from factors outside Maralvion’s reasonable control, from User settings or conduct, or from circumstances described in this App EULA.
25.8 Subject to Articles 25.1 to 25.3, Maralvion is not liable for medical decisions, treatment decisions, insulin dosing, medication adjustments, dietary actions, exercise decisions, emergency decisions or other health related actions taken by you or another person based on the App, except where mandatory applicable law provides otherwise.
25.9 Subject to Articles 25.1 to 25.3, Maralvion is not liable for further disclosure, misuse, copying, forwarding, storage, interpretation or use of information by a Share and Follow recipient, except where Maralvion is legally responsible under mandatory applicable law.
25.10 Subject to Articles 25.1 to 25.3, Maralvion is not liable for damage caused by unauthorised access to your Account or mobile device where such access results from your failure to protect your login details, mobile device, email account, password, biometric access or security settings.
25.11 Dreisam remains responsible, as legal Manufacturer, for the aspects of the GlucoSensor™ Q System that fall within the Manufacturer’s responsibility, including System design, Sensor technology, the Manufacturer SDK, manufacturer supplied or manufacturer authorised software components and the manufacturer controlled functionality used to generate glucose related information. This does not extend Maralvion’s role beyond the roles expressly described in this App EULA and does not limit any mandatory obligation imposed on Maralvion by applicable law.
25.12 Subject to Articles 25.1 to 25.3, Maralvion’s liability for indirect damage, consequential damage, loss of profit, loss of business, loss of revenue, loss of goodwill, loss of anticipated savings, business interruption or other commercial losses is excluded to the maximum extent permitted by applicable law. This exclusion does not apply to liability that cannot lawfully be excluded or limited.
25.13 Where liability cannot be excluded but may be limited under applicable law, Maralvion’s liability is limited to the maximum extent permitted by mandatory applicable law.
ARTICLE 26. SUSPENSION AND TERMINATION
26.1 You may stop using the App at any time by discontinuing use and removing the App from your mobile device.
26.2 Termination of App use does not automatically close your Account or terminate any Website account functionality, purchase agreement, subscription, support case, warranty claim, replacement request, refund request, legal obligation or data retention obligation that exists independently of this App EULA.9.10
26.3 Maralvion may suspend, restrict or terminate your access to the App where reasonably necessary because of an actual or suspected breach of this App EULA, misuse, fraud, unlawful activity, safety risk, cybersecurity risk, regulatory concern, unauthorised use, unsupported technical configuration, non payment where applicable, App Store requirement or legal obligation.
26.4 Maralvion may suspend, restrict or terminate access to the App where continued access may affect the safety, security, integrity, availability, regulatory compliance or proper operation of the App, the GlucoSensor Q System, other Users, Maralvion systems, Dreisam systems or service provider systems.
26.5 Where reasonably possible, Maralvion will notify you of suspension, restriction or termination, unless immediate action is required or notification would be unlawful, unsafe, impractical or harmful to security, regulatory compliance or other Users.
26.6 Suspension, restriction or termination by Maralvion will be proportionate to the reason for the action where required by mandatory applicable law and where this is compatible with safety, security and regulatory obligations.
26.7 Upon termination, your right to use the App ends and you must stop using the App.
26.8 Clauses that by their nature are intended to continue after termination remain in force, including clauses concerning medical device safety, user responsibilities, prohibited use, data protection, security, intellectual property rights, limitation of liability, governing law, dispute handling and regulatory cooperation.
26.9 Personal Data and Health Data will be retained or deleted after termination in accordance with the Privacy Policy, applicable data protection law, medical device obligations, legal retention obligations and legitimate regulatory or legal requirements.
ARTICLE 27. CHANGES TO THIS APP EULA
27.1 Maralvion may update this App EULA where there is a valid reason to do so, including changes in the App, GlucoSensor Q, applicable law, regulatory requirements, Digital Content Laws, App Store requirements, technical requirements, security requirements, company structure, service providers, support processes or business operations.
27.2 The version number and effective date at the beginning of this App EULA indicate the applicable version.
27.3 Where changes are material, Maralvion will take reasonable steps to inform Users through the App, Website, email or another appropriate communication channel before or when the updated App EULA takes effect, depending on the nature and urgency of the change.
27.4 Where a material change negatively affects your access to or use of the App in more than a minor way and mandatory applicable law requires specific notice or termination rights, Maralvion will provide information on the nature of the change, the effective date, the reason for the change and any statutory right to end the relevant contract without additional charge.
27.5 Continued use of the App after the effective date of an updated App EULA constitutes acceptance of the updated App EULA only where legally permitted. Where mandatory applicable law requires express acceptance, the updated App EULA will apply after such acceptance or from another legally valid point in time.
27.6 If you do not agree to an updated App EULA, you must stop using the App. Any mandatory rights that you may have in relation to digital content, digital services, purchases, subscriptions or consumer remedies remain unaffected.
27.7 Changes to this App EULA do not limit mandatory consumer rights, mandatory Digital Content Laws, mandatory medical device rights, mandatory data protection rights or other mandatory rights that cannot be limited under applicable law.
ARTICLE 28. GOVERNING LAW, CONSUMER RIGHTS AND DISPUTES
28.1 This App EULA is governed by the laws of Poland, without prejudice to any mandatory consumer protection rights that may apply under the laws of the country where you have your habitual residence.
28.2 If you are a consumer residing in the European Union, you may benefit from mandatory consumer protection provisions of your country of residence where such provisions apply by law.
28.3 Maralvion aims to resolve questions, complaints and disputes through its official support channels before escalation.
28.4 You may contact Maralvion at support@glucosensor.com for questions or complaints concerning the App, this App EULA, technical issues, support matters, product related complaints or other matters relating to GlucoSensor Q.
28.5 Nothing in this App EULA prevents you from exercising mandatory rights before a competent court, authority or other body where you have the right to do so under mandatory applicable law.
28.6 If any provision of this App EULA is found to be invalid, unlawful or unenforceable, the remaining provisions remain in full force and effect. The invalid, unlawful or unenforceable provision will be interpreted or replaced, to the extent permitted by law, by a valid provision that most closely reflects its purpose.
28.7 This App EULA has been drafted in English. Maralvion may make translations or local-language versions of this App EULA available through the App, Website, Account environment, App Store materials, customer support, translation functionality or other communication channels for user convenience, App functionality, market access, customer information or compliance support. To the extent permitted by mandatory applicable law, the English version is the leading and controlling version for interpretation where there is an ambiguity, discrepancy or inconsistency between the English version and any translated or local-language version of this App EULA. Translated and local-language versions should be interpreted consistently with the English version as far as legally possible. If a translated or local-language version appears unclear, incomplete or inconsistent, Maralvion may correct, update or clarify that version. This Article does not exclude or reduce mandatory local consumer protection requirements, medical device language requirements, data protection transparency requirements or national rules governing the language in which contractual, consumer, privacy, product or safety information must be supplied, interpreted or made available. Where a linguistic discrepancy concerns safe or correct use, intended purpose, indications, contraindications, warnings, precautions, Product performance, Product labelling, the IFU, App warnings, mandatory regulatory information or safety notices, the applicable manufacturer-approved IFU, Product labelling, mandatory regulatory information and safety notices supplied in the language required by applicable law prevail for that specific matter.
ARTICLE 29. CONTACT INFORMATION
29.1 Questions regarding this App EULA, the App, GlucoSensor Q, Account access, technical support, product support, complaints, safety related reporting or other App related matters may be directed to:
Maralvion sp. z o.o.
Pl. Władysława Andersa 3
11th Floor
61-894 Poznań
Poland
KRS: 0001235440
NIP: 7831951730
REGON: 544505977
Email: support@glucosensor.com
Website: www.glucosensor.com
29.2 Product support requests, technical support requests, complaint submissions, safety related reports, warranty requests, replacement requests and medical device related enquiries should be submitted through the official GlucoSensor support channels made available through the Website or App.
29.3 Privacy related questions, requests concerning Personal Data or Health Data and the exercise of data protection rights should be submitted in accordance with the Privacy Policy or by contacting support@glucosensor.com.
29.4 Where required, Maralvion may handle or forward product related reports in accordance with applicable medical device obligations.
29.5 For urgent medical questions, serious symptoms, suspected hypoglycaemia, suspected hyperglycaemia or medical emergencies, you must contact a qualified healthcare professional or emergency medical services. Maralvion support is not an emergency medical service.